Rhythm Pharmaceuticals, Inc. (RYTM): Price and Financial Metrics


Rhythm Pharmaceuticals, Inc. (RYTM)

Today's Latest Price: $28.96 USD

0.02 (-0.07%)

Updated Dec 4 4:00pm

Add RYTM to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

RYTM Stock Price Chart Interactive Chart >

Price chart for RYTM

RYTM Price/Volume Stats

Current price $28.96 52-week high $34.27
Prev. close $28.98 52-week low $12.99
Day low $27.70 Volume 727,200
Day high $29.27 Avg. volume 266,231
50-day MA $23.85 Dividend yield N/A
200-day MA $21.19 Market Cap 1.28B

Rhythm Pharmaceuticals, Inc. (RYTM) Company Bio


Rhythm Pharmaceuticals, Inc. develops and commercializes peptide therapeutics for the treatment of rare genetic disorders of obesity in the United States. Its lead product candidate is Setmelanotide, a melanocortin-4 receptor agonist that is in Phase III clinical trials for treating POMC deficiency obesity and leptin receptor deficiency obesity; and Phase II clinical trials for treating Bardet-Biedl syndrome, Alström syndrome, POMC heterozygous deficiency obesity, and POMC epigenetic disorders. The company was founded in 2008 and is based in Boston, Massachusetts.


RYTM Latest News Stream


Event/Time News Detail
Loading, please wait...

RYTM Latest Social Stream


Loading social stream, please wait...

View Full RYTM Social Stream

Latest RYTM News From Around the Web

Below are the latest news stories about Rhythm Pharmaceuticals Inc that investors may wish to consider to help them evaluate RYTM as an investment opportunity.

Rhythm Pharmaceuticals EPS beats by $0.12

Rhythm Pharmaceuticals (RYTM): Q2 GAAP EPS of -$0.71 beats by $0.12.Cash, cash equivalents and short-term investments of $228.6MPress Release...

Seeking Alpha | August 3, 2020

Rhythm Pharma names new CEO

Rhythm Pharmaceuticals ([[RYTM]] +0.8%) appoints David Meeker,  the company's chairman as the President and CEO, effective immediately.Dr. Meeker succeeds Hunter Smith, the Company’s Interim President & CEO and CFO, who will continue in his role as CFO.Dr. Meeker has served as Chairman of Rhythm Pharmaceuticals since April 2017 and as board member...

Seeking Alpha | July 20, 2020

Rhythm Pharmaceuticals Announces Appointment of David Meeker, M.D., as Chief Executive Officer

BOSTON, July 20, 2020 -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment.

Yahoo | July 20, 2020

Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide in Bardet-Biedl Syndrome in Diabetes, Obesity and Metabolism

\-- Study demonstrated that treatment with setmelanotide reduced body weight and hunger in individuals living with Bardet-Biedl syndrome -- BOSTON, July 16, 2020 -- Rhythm.

Yahoo | July 16, 2020

Rhythm Pharmaceuticals Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Setmelanotide for Treatment of POMC and LEPR Deficiency Obesities

Rhythm Pharmaceuticals, Inc. (RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designations for setmelanotide, an investigational melanocortin-4 receptor (MC4R) agonist, for the treatment of pro-opiomelanocortin (POMC) deficiency obesity and leptin receptor (LEPR) deficiency obesity. As previously announced, the Company’s New Drug Application (NDA) for setmelanotide was accepted for filing with priority review by the FDA and assigned a Prescription Drug User Fee Act (PDUFA) goal date of November 27, 2020.

Yahoo | July 1, 2020

Read More 'RYTM' Stories Here

RYTM Price Returns

1-mo 23.60%
3-mo -3.08%
6-mo 42.17%
1-year 21.32%
3-year 0.98%
5-year N/A
YTD 26.13%
2019 -14.58%
2018 -7.50%
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8122 seconds.